RFI for Clinician Advisory Services
Federal opportunity from 44090 - Division of Financial Regulation | 9001 - DFR Admin • Department of Consumer and Business Services. Place of performance: OR. Response deadline: Jan 30, 2026.
Market snapshot
Baseline awarded-market signal across all contracting (sample of 400 recent awards; refreshed periodically).
Related hubs & trends
Navigate the lattice: hubs for browsing, trends for pricing signals.
Applicable Wage Determinations
SAM WDOL references matched to this opportunity's location and scope language.
View more for this contract3 more WD matches and 46 more rate previews.↓
Point of Contact
Agency & Office
Description
RFI for Clinician Advisory Services
This request for information (RFI) is issued by the State of Oregon, Department of Consumer and Business Services, Division of Financial Regulation (Agency) to seek Clinician Advisory Services for the Oregon Prescription Drug Affordability Board to consider.
Files
Files size/type shown when available.
BidPulsar Analysis
A practical, capture-style breakdown of fit, requirements, risks, and next steps.
The State of Oregon is seeking information through an RFI for Clinician Advisory Services aimed at supporting the Oregon Prescription Drug Affordability Board. Responses are due by January 30, 2026. This initiative is expected to enhance the Board's capacity to address prescription drug pricing challenges in Oregon.
The buyer is looking for Clinician Advisory Services to provide insights and recommendations to the Oregon Prescription Drug Affordability Board to effectively manage and evaluate prescription drug pricing strategies.
- Healthcare consulting firms
- Organizations with expertise in pharmaceutical pricing
- Clinical advisory services providers
- Research and analysis of current prescription drug pricing trends.
- Recommendations for policies and regulations concerning drug affordability.
- Advisory services to assess the impact of prescription drug costs on consumers.
- Cover letter
- Company profile
- Relevant experience
- Proposed methodologies
- References and case studies
More BidPulsar strategy notesCompliance, pricing, teaming, risks, questions, and coverage notes
- Ensure alignment with Oregon state regulations on healthcare
- Confidentiality agreements may be required
- Comply with ethical guidelines in pharmaceutical advisory
- Outline hourly rates or fixed pricing for advisory services
- Consider including tiered pricing based on the depth of analysis required
- Provide cost estimates for various scopes of work
- Consider teaming with healthcare economists
- Partnerships with data analysis firms may strengthen proposals
- Involve clinicians with experience in drug affordability
- Incomplete understanding of Oregon's regulatory frameworks
- Potential conflicts of interest with pharmaceutical companies
- Limitations in available data for analysis
- What specific outcomes does the Oregon Prescription Drug Affordability Board expect?
- What constraints or challenges should be anticipated in delivering these advisory services?
- Are there existing reports or studies that would inform our proposals?
Some notices publish limited source detail. Confirm these points before final bid/no-bid decisions.
- Specific deliverables expected from the RFI
- Clarification on evaluation criteria for the responses
- Deadline for questions regarding the RFI
- Budget constraints or funding limitations
- Preferred communication channels for submission
FAQ
How do I use the Market Snapshot?
It summarizes awarded-contract behavior for the opportunity’s NAICS and sector, including a recent pricing band (P10–P90), momentum, and composition. Use it as context, not a guarantee.
Is the data live?
The signal updates as new awarded notices enter the system. Always validate the official award and solicitation details on SAM.gov.
What do P10 and P90 mean?
P10 is the 10th percentile award size and P90 is the 90th percentile. Together they describe the typical spread of award values.